IN3 Europe Banner

Read more »

Implantable Weight-Loss Device Receives CE Mark Approval

GI Dynamics has received European CE mark approval to commercialize a non-surgical device for the management of obesity and Type 2 diabetes.

Read more »

Resverlogix to Begin Phase II Atherosclerosis Trial

Canadian biopharmaceutical company Resverlogix has commenced a Phase II clinical trial for RVX-208, its small molecule therapy for the treatment of atherosclerosis in patients with stable coronary artery disease.

Read more »

Researchers Identify Gene Linked to Childhood Asthma

U.S. researchers have identified a gene that is linked to childhood asthma.

Read more »

Clarient Acquires AGI In All-Stock Merger

Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Applied Genomics in an all-stock merger worth up to $17.6 million.

Read more »

Ambit and Astellas Sign $350M Development Deal

The deal will include Ambit’s AC220, a kinase inhibitor currently in Phase II trials to treat a form of blood cancer called acute relapsed/refractory myeloid leukemia (AML).

Read more »

Possible Cause of Inflammatory Bowel Disease Uncovered

A researcher at the University of Adelaide found that people suffering from inflammatory bowel disease have a lower number of regulatory cells that control the immune system.

Read more »

Cubist/Calixa Deal the Latest in a String of Biotech Buyouts

Cubist Pharmaceuticals has announced plans to acquire tiny San Diego biotech Calixa Therapeutics for up to $402.5 million.

Read more »

[Company Profile] MicroPhage

MicroPhage of Longmont, Colo., has developed a platform of rapid diagnostic tests to identify staph bacteria and determine methicillin resistance (MRSA) and susceptibility (MSSA).

Read more »